加拿大卫生研究院对抗菌素耐药性的应对措施。
The Canadian Institutes of Health Research response to antimicrobial resistance.
作者信息
Pagé E L, Desnoyers S, Létourneau I J, Keown K, Jackson A, Ouellette M
机构信息
Canadian Institutes of Health Research, Institute of Infection and Immunity, Québec, QC.
Canadian Institutes of Health Research, Ottawa, ON.
出版信息
Can Commun Dis Rep. 2015 Nov 19;41(Suppl 5):11-15. doi: 10.14745/ccdr.v41is5a03.
Abstract
Antimicrobial resistance (AMR) has been a research priority for the Canadian Institutes of Health Research (CIHR), Institute of Infection and Immunity (III) since its inception, and a number of strategic research initiatives have been launched to address this global health problem by promoting and supporting research related to mechanisms and processes that impact the emergence and spread of resistance among individuals and within the environment. Here we will present research initiatives on AMR led by CIHR-III, which include national programs as well as international partnerships with the United Kingdom and the European Union, in addition to interesting outcomes of these initiatives.
摘要
自成立以来，抗菌药物耐药性（AMR）一直是加拿大卫生研究院（CIHR）感染与免疫研究所（III）的研究重点。通过促进和支持与影响个体及环境中耐药性产生和传播的机制及过程相关的研究，已经启动了多项战略研究计划来解决这一全球健康问题。在此，我们将介绍由CIHR-III牵头的关于抗菌药物耐药性的研究计划，其中包括国家项目以及与英国和欧盟的国际合作关系，此外还将介绍这些计划取得的有趣成果。
相似文献
1
The Canadian Institutes of Health Research response to antimicrobial resistance.加拿大卫生研究院对抗菌素耐药性的应对措施。
Can Commun Dis Rep. 2015 Nov 19;41(Suppl 5):11-15. doi: 10.14745/ccdr.v41is5a03.
2
Canadian Senior Renal Leaders Community of Practice: Vulnerable Populations With Chronic Kidney Disease-Evidence to Inform Policy.加拿大老年肾脏科专家实践社区：慢性肾脏病脆弱人群——为政策提供信息的证据
Can J Kidney Health Dis. 2020 Jul 24;7:2054358120930977. doi: 10.1177/2054358120930977. eCollection 2020.
3
Antimicrobial use and antimicrobial resistance trends in Canada: 2014.加拿大2014年抗菌药物使用及耐药性趋势
Can Commun Dis Rep. 2016 Nov 3;42(11):227-231. doi: 10.14745/ccdr.v42i11a02.
4
The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.以学校为基础的家庭哮喘教育项目对5至18岁确诊哮喘儿童生活质量和哮喘发作次数的有效性：一项系统评价方案
JBI Database System Rev Implement Rep. 2015 Oct;13(10):69-81. doi: 10.11124/jbisrir-2015-2335.
5
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.淋病奈瑟菌的耐药性：STAR 性传播感染临床研究组计划会议记录。
Sex Transm Dis. 2019 Mar;46(3):e18-e25. doi: 10.1097/OLQ.0000000000000929.
6
The Revolution in Health Research.健康研究的革命
Clin Invest Med. 2018 Nov 3;41:9-10. doi: 10.25011/cim.v41i2.31410.
7
Involving citizens and patients in health research.让公民和患者参与健康研究。
J Ambul Care Manage. 2010 Jul-Sep;33(3):215-22. doi: 10.1097/JAC.0b013e3181e62bd7.
8
Fighting Antimicrobial Resistance and Healthcare-Associated Infections in EU-JAMRAI: The One-Health Response from Italy.抗击欧盟抗菌药物耐药性和医疗机构相关感染的联合行动计划：意大利的“同一健康”应对措施。
Chemotherapy. 2024;69(1):56-64. doi: 10.1159/000531684. Epub 2023 Sep 6.
9
[Public, private, and public-private partnerships to implement One Health as an action to address antimicrobial resistance in ColombiaParcerias públicas, privadas e público-privadas para a implementação da Saúde Única como uma ação contra a resistência a antimicrobianos na Colômbia].[公私合营伙伴关系在哥伦比亚实施“同一健康”以应对抗菌药物耐药性的行动]
Rev Panam Salud Publica. 2023 Apr 28;47:e64. doi: 10.26633/RPSP.2023.64. eCollection 2023.
10
Antimicrobial resistance and universal health coverage.抗微生物药物耐药性与全民健康覆盖
BMJ Glob Health. 2017 Oct 31;2(4):e000518. doi: 10.1136/bmjgh-2017-000518. eCollection 2017.
本文引用的文献
1
Antimicrobial resistance and use in Canada: A federal framework for action.加拿大的抗菌素耐药性与使用：联邦行动框架
Can Commun Dis Rep. 2014 Nov 7;40(Suppl 2):2-5. doi: 10.14745/ccdr.v40is2a01.
2
Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase.针对细菌细胞壁生物合成抑制剂的拮抗筛选发现了一种十一异戊烯基二磷酸合酶抑制剂。
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11048-53. doi: 10.1073/pnas.1511751112. Epub 2015 Aug 17.
3
Arginine-containing peptides as potent inhibitors of VIM-2 metallo-β-lactamase.含精氨酸肽作为VIM-2金属β-内酰胺酶的强效抑制剂。
Biochim Biophys Acta. 2015 Nov;1850(11):2228-38. doi: 10.1016/j.bbagen.2015.07.012. Epub 2015 Aug 1.
4
Assay for drug discovery: Synthesis and testing of nitrocefin analogues for use as β-lactamase substrates.药物发现检测：用作β-内酰胺酶底物的头孢硝噻吩类似物的合成与测试。
Anal Biochem. 2015 Oct 1;486:75-7. doi: 10.1016/j.ab.2015.06.032. Epub 2015 Jul 2.
5
The biology of Mur ligases as an antibacterial target.Mur连接酶作为抗菌靶点的生物学特性。
Mol Microbiol. 2014 Oct;94(2):242-53. doi: 10.1111/mmi.12758. Epub 2014 Sep 5.
6
Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.气溶胶噬菌体疗法在洋葱伯克霍尔德菌复合体呼吸道感染中的疗效
Antimicrob Agents Chemother. 2014 Jul;58(7):4005-13. doi: 10.1128/AAC.02388-13. Epub 2014 May 5.
7
Discovery of novel cell wall-active compounds using P ywaC, a sensitive reporter of cell wall stress, in the model gram-positive bacterium Bacillus subtilis.在模式革兰氏阳性菌枯草芽孢杆菌中，利用细胞壁应激敏感报告基因P ywaC发现新型细胞壁活性化合物。
Antimicrob Agents Chemother. 2014 Jun;58(6):3261-9. doi: 10.1128/AAC.02352-14. Epub 2014 Mar 31.
8
Characterization of cefoxitin-resistant Escherichia coli isolates from recreational beaches and private drinking water in Canada between 2004 and 2006.2004年至2006年期间从加拿大休闲海滩和私人饮用水中分离出的耐头孢西丁大肠杆菌菌株的特性分析
Antimicrob Agents Chemother. 2009 Jul;53(7):3126-30. doi: 10.1128/AAC.01353-08. Epub 2009 Apr 27.
9
Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study.加拿大急症护理医院收治的成年患者中与医疗保健相关的艰难梭菌感染：一项加拿大医院感染监测项目研究
Clin Infect Dis. 2009 Mar 1;48(5):568-76. doi: 10.1086/596703.
10
Antimicrobial susceptibilities of Campylobacter jejuni isolates from poultry from Alberta, Canada.来自加拿大艾伯塔省家禽的空肠弯曲菌分离株的抗菌药敏性。
Antimicrob Agents Chemother. 2006 Feb;50(2):778-80. doi: 10.1128/AAC.50.2.778-780.2006.
Zotero 插件